{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:32Z","timestamp":1793898272775,"version":"4.8.0"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials. The purpose was to expand the pool of patients for safety analyses and to increase power for efficacy analyses in patient subpopulations<jats:italic>.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Aurinia Urinary Protein Reduction in Active Lupus with Voclosporin (AURA\u2010LV) (phase II) and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA 1) (phase III) were randomized, placebo\u2010controlled, double\u2010blind trials with similar designs and end points comparing voclosporin to control in combination with MMF and oral glucocorticoids for the treatment of LN. The primary efficacy outcome of the integrated analysis was complete renal response (CRR) at approximately one year (Week 48 data from AURA\u2010LV and Week 52 from AURORA 1). Safety was assessed throughout the trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 534 patients (268 voclosporin; 266 control) were included in the integrated analysis. Significantly more patients achieved a CRR at one year in the voclosporin group than in the control group (43.7% vs. 23.3%; OR 2.76; 95% CI 1.88, 4.05 <jats:italic>P<\/jats:italic> &lt;\u20090.0001). The incidence of adverse events (AEs) was similar (91.4% voclosporin; 87.2% control). Most AEs were mild to moderate in severity; the most commonly reported AEs were classified as infections and infestations (62.2% voclosporin; 54.9% control) and gastrointestinal disorders (45.3% voclosporin; 35.3% placebo). No new or unexpected safety signals were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This integrated analysis demonstrates the efficacy and safety of voclosporin in the treatment of LN across the diverse racial and ethnic groups studied.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.25007","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:14:18Z","timestamp":1661843658000},"page":"1399-1408","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis"],"prefix":"10.1002","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1664","authenticated-orcid":false,"given":"Cristina","family":"Arriens","sequence":"first","affiliation":[{"name":"Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center  Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y. K. Onno","family":"Teng","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Ginzler","sequence":"additional","affiliation":[{"name":"SUNY Downstate Health Sciences University  Brooklyn New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir V.","family":"Parikh","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center  Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5023","authenticated-orcid":false,"given":"Anca D.","family":"Askanase","sequence":"additional","affiliation":[{"name":"Columbia University Lupus Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-1083","authenticated-orcid":false,"given":"Amit","family":"Saxena","sequence":"additional","affiliation":[{"name":"New York University School of Medicine  New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-8150","authenticated-orcid":false,"given":"Keisha","family":"Gibson","sequence":"additional","affiliation":[{"name":"University of North Carolina Kidney Center  Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn J.","family":"Caster","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine  Louisville Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Hokkaido University  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lisk","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc.  Victoria British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-2843","authenticated-orcid":false,"given":"Simrat","family":"Randhawa","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc.  Victoria British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashieda","family":"Gluck","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc.  Victoria British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Solomons","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc.  Victoria British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-7655","authenticated-orcid":false,"given":"Robert B.","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc.  Victoria British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135186"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-016-0051-x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000108969.21691.5D"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320932219"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206897"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39026"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161554"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft201"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311418269"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00212-9"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.11.002"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03763.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab022"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.933332"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.025"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000123"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep346"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000243"},{"key":"e_1_2_6_25_1","first-page":"1188","article-title":"Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans","volume":"51","author":"Dooley MA","year":"1997","journal-title":"Glomerular Disease Collaborative Network. Kidney Int"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel039"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg345"},{"key":"e_1_2_6_28_1","first-page":"9","article-title":"Efficacy of voclosporin in recent onset lupus nephritis [abstract]. Arthritis","volume":"73","author":"Mackay MT","year":"2021","journal-title":"Rheumatol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1681\/ASN.20213210S148b","article-title":"Voclosporin is effective in achieving complete renal response in severe lupus nephritis [abstract]","volume":"32","author":"Menn\u2010Josephy H","year":"2021","journal-title":"Am Soc Nephrol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31827f4ee3"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319842924"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102898"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120537"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa162"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.25007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:56:39Z","timestamp":1759420599000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,12]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/acr.25007"],"URL":"https:\/\/doi.org\/10.1002\/acr.25007","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,12]]},"assertion":[{"value":"2022-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}